Skip to main content
. 2012 Aug 1;122(8):2731–2740. doi: 10.1172/JCI60331

Figure 2. Mortality in ALI and ARDS.

Figure 2

Shown is the 60-day mortality reported over the last 11 years in randomized clinical trials from the ARDS Network. ARMA-12 refers to the mortality rate of 431 patients enrolled into the higher–tidal volume arm (12 ml tidal volume/kg predicted body weight), and ARMA-6 refers to the mortality of 430 patients enrolled in the lower–tidal volume arm (6 ml tidal volume/kg predicted body weight) of one study (97). FACTT fluid conservative refers to the mortality of the 500 patients enrolled into the fluid-conservative arm of the Fluid and Catheter Treatment Trial (120). ALTA and OMEGA refer to the combined mortalities of the 2 most recent trials (N = 517 in both trials combined), Albuterol for the Treatment of ALI (136) and Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Antioxidant Supplementation in the Management of ALI or ARDS (138).